Accounts Receivable, after Allowance for Credit Loss, Current of Nurix Therapeutics, Inc. from 31 May 2021 to 31 May 2025

Taxonomy & unit
us-gaap: USD
Description
Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.
Summary
Nurix Therapeutics, Inc. quarterly Accounts Receivable, after Allowance for Credit Loss, Current in USD history and change rate from 31 May 2021 to 31 May 2025.
  • Nurix Therapeutics, Inc. Accounts Receivable, after Allowance for Credit Loss, Current for the quarter ending 31 May 2025 was $19,000,000.
Source SEC data
View on sec.gov
Accounts Receivable, after Allowance for Credit Loss, Current, Quarterly (USD)

Nurix Therapeutics, Inc. Quarterly Accounts Receivable, after Allowance for Credit Loss, Current (USD)

Period Value YoY Chg Change % Date Report Filed Fiscal Year Fiscal Period
Q2 2025 $19,000,000 31 May 2025 10-Q 09 Jul 2025 2025 Q2
Q4 2024 $0 30 Nov 2024 10-Q 09 Jul 2025 2025 Q2
Q3 2023 $2,000,000 31 Aug 2023 10-Q 12 Oct 2023 2023 Q3
Q4 2022 $0 30 Nov 2022 10-Q 12 Oct 2023 2023 Q3
Q2 2021 $2,537,000 31 May 2021 10-Q 13 Jul 2021 2021 Q2
* An asterisk sign (*) next to the value indicates that the value is likely invalid.